Review finds GLP-1 medicines may help some children with obesity or type 2 diabetes, but long-term safety data are still limited
A pediatric review found GLP-1 medicines may help selected children and teens with obesity or...
Retatrutide: A New Horizon in Diabetes and Obesity Management
Retatrutide: A New Horizon in Diabetes and Obesity Management: evidence-based guidance reviewed against current NICE...
Retatrutide Phase 3 Results: What People With Type 2 Diabetes Should Know
Phase 3 retatrutide data in recent-onset type 2 diabetes showed A1C lowering and weight loss...
Orforglipron vs Dapagliflozin in Type 2 Diabetes: What the ACHIEVE-2 Trial Found
ACHIEVE-2 compared oral orforglipron with dapagliflozin in adults with type 2 diabetes. Learn about HbA1c...
Omnipod Pod Correction: Under-Delivery Risk and What Users Should Check
Omnipod pod correction guide covering affected products, insulin under-delivery, high glucose, DKA risk, lot checks...
New Research Confirms GLP-1 Medications Protect the Heart, Not Just Blood Sugar
New Research Confirms GLP-1 Medications Protect the Heart, Not Just Blood Sugar: cardiovascular outcome trial...
Insulin cost caps help some commercially insured adults, but many insulin users remain unprotected
New Diabetes Care research explains why state insulin cost caps help some people, but leave...
Inflammation and Heart-Failure Risk in Type 2 Diabetes: What the Look AHEAD Study Found
New Look AHEAD findings connect IL-6 with heart-failure risk in type 2 diabetes, but do...
Human vs Analogue Insulin in Young People With Type 1 Diabetes: What the HumAn-1 Trial Found
The HumAn-1 trial found no clear CGM advantage for glargine over usual-care human insulin regimens...